baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Put 930 REGN 17.05.2024/ DE000JK0U881 /

10/05/2024 14:07:05	Chg.-0.037	Bid22:00:38	Ask22:00:38	Underlying	Strike price	Expiration date	Option type
0.006EUR	-86.05%	- Bid Size: -	- Ask Size: -	Regeneron Pharmaceut...	930.00 USD	17/05/2024	Put

GlobeNewswire 10/05 Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 09/05 Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...

GlobeNewswire 08/05 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 07/05 Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

GlobeNewswire 06/05 Regeneron Announces Investor Conference Presentations

GlobeNewswire 02/05 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 29/04 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 26/04 Medigene AG reports Financial Results and Business Update for Q1 2024

GlobeNewswire 25/04 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 24/04 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 23/04 Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

GlobeNewswire 22/04 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 18/04 Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...

GlobeNewswire 18/04 REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...

GlobeNewswire 16/04 Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

GlobeNewswire 16/04 Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

GlobeNewswire 15/04 Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation

GlobeNewswire 11/04 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...

GlobeNewswire 09/04 Opthea Appoints John Han, PharmD, as VP Medical Affairs

GlobeNewswire 07/04 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...

GlobeNewswire 01/04 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...

GlobeNewswire 25/03 Regeneron Provides Update on Biologics License Application for Odronextamab

GlobeNewswire 22/03 Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm

GlobeNewswire 20/03 Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

GlobeNewswire 18/03 CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards

JP Morgan Put 930 REGN 17.05.2024/ DE000JK0U881 /

If you wish to receive reply to your feedback, please provide your email address.